CureDuchenne Ventures invests in Insmed Incorporated to support the development of a next-generation gene therapy with targeted intrathecal delivery and the potential to produce a larger dystrophin construct.

Insmed RNA DMD

CureDuchenne Ventures announces an investment in Insmed Incorporated to support the development of INS1201, their next generation gene therapy candidate with a targeted delivery approach designed with the potential to address some of the current limitations of gene therapy. Insmed is also exploring the potential of its RNA end-joining technology to deliver larger dystrophin constructs with a goal of ultimately delivering full-length dystrophin protein. 


Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.